Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Lundbeck

Market Cap 41.9B 6.5B 5.61B 5.16B 4.84B 9.09B 615B 9.18B 60.99B 23.82B 301B 24.41B 23.89B 1,042B P/E Ratio 2026 *
9.7x
P/E Ratio 2027 * 9.48x
Enterprise Value 45.99B 7.14B 6.15B 5.66B 5.31B 9.98B 675B 10.08B 66.96B 26.15B 330B 26.79B 26.23B 1,143B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.63x
Free-Float
30.76%
Yield 2026 *
3.37%
Yield 2027 * 3.45%
1 day-0.14%
1 week+1.53%
Current month-0.68%
1 month+4.43%
3 months+7.03%
6 months+4.13%
Current year+0.97%
1 week 35.65
Extreme 35.65
37.3
1 month 34.75
Extreme 34.75
37.55
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 66 24/03/2015
Director/Board Member 60 19/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.53% - - 6.49B
-0.75%+1.46%+8.10%+94.43% 91.79B
+0.79%+10.25%+38.80%+152.84% 52.43B
+6.06%-4.11%-13.85%+229.41% 21.42B
-0.37%+0.12%-11.28%-26.90% 8.13B
-0.38%+2.04%-34.90%-30.42% 7.54B
-0.41%-1.63%-11.82%-36.59% 6.77B
-1.00%+0.06%-2.55%+17.62% 5.32B
+1.67%-2.01%-10.48%-14.79% 3.53B
-1.08%-2.36%+10.15%+10.31% 3.37B
Average +0.48%+0.67%-3.09%+43.99% 22.26B
Weighted average by Cap. +0.41%+1.97%+10.13%+104.72%

Financials

2026 *2027 *
Net sales 25.7B 3.99B 3.44B 3.17B 2.97B 5.58B 377B 5.63B 37.42B 14.62B 185B 14.97B 14.66B 639B 25.74B 4B 3.44B 3.17B 2.97B 5.58B 378B 5.64B 37.46B 14.63B 185B 14.99B 14.67B 640B
Net income 4.71B 731M 630M 580M 544M 1.02B 69.11B 1.03B 6.86B 2.68B 33.84B 2.74B 2.69B 117B 4.81B 746M 643M 592M 555M 1.04B 70.53B 1.05B 7B 2.73B 34.54B 2.8B 2.74B 120B
Net Debt 4.1B 636M 548M 505M 473M 889M 60.13B 898M 5.97B 2.33B 29.44B 2.39B 2.34B 102B -30.08M -4.67M -4.02M -3.7M -3.47M -6.53M -441M -6.59M -43.79M -17.1M -216M -17.52M -17.15M -748M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
15/06/26 36.55 kr 0.00% 62,560
12/06/26 36.55 kr -1.48% 54,355
11/06/26 37.10 kr +0.27% 39,971
10/06/26 37.00 kr +2.78% 88,977
09/06/26 36.00 kr 0.00% 54,107
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
43.70DKK
Average target price
47.21DKK
Spread / Average Target
+8.03%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!